載入...
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
BACKGROUND: Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious adverse events (SAEs) or fatal adverse event...
Na minha lista:
| 發表在: | J Immunother Cancer |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6171173/ https://ncbi.nlm.nih.gov/pubmed/30285872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0421-z |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|